Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes

BACKGROUND: EDC1 is a novel type of antibody-drug conjugate which binds and inhibits the Na,K-ATPase on the surface of cancer cells expressing dysadherin. The purpose of this study was to determine the expression of dysadherin in different types of thyroid carcinoma, and evaluate the therapeutic pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Samuel, Yu, Xiao-Min, Montemayor-Garcia, Celina, Ahmed, Kamal, Weinlander, Eric, Lloyd, Ricardo V., Dammalapati, Ajitha, Marshall, David, Prudent, James R., Chen, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421862/
https://www.ncbi.nlm.nih.gov/pubmed/28160550
http://dx.doi.org/10.18632/oncotarget.14904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421862/
https://www.ncbi.nlm.nih.gov/pubmed/28160550
http://dx.doi.org/10.18632/oncotarget.14904

Ejemplares similares